Rankings
▼
Calendar
▼
AAPG Q4 2016 Earnings Report — Ascentage Pharma Group International Revenue & Financial Results | Market Cap Arena
Ascentage Pharma Group International
AAPG
Q4 2016 Earnings
Reported December 31, 2016
Quarter Comparison
Revenue
Operating Income
Gross Margin
Net Margin
EPS (Diluted)
Free Cash Flow
Metric
Q4 2016
Q3 2016
Q4 2015
QoQ Change
YoY Change
Revenue
$560.1K
—
—
—
—
Op. Income
-$8M
—
—
—
—
Gross Margin
96.6%
—
—
—
—
Net Margin
-1406.5%
—
—
—
—
EPS (Diluted)
$-0.61
—
—
—
—
Free Cash Flow
-$4M
—
—
—
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$560.1K
Cost of Revenue
$19.1K
GROSS PROFIT
$541.1K
R&D Expenses
$8M
Selling & Marketing
$0
General & Administrative
$1M
SG&A Expenses
$1M
Other Expenses
$119.0K
Operating Expenses
$9M
Cost & Expenses
$9M
OPERATING INCOME
-$8M
Interest Income
$950
Interest Expense
$238.1K
Other Income/Expenses
$495.6K
INCOME BEFORE TAX
-$8M
Income Tax Expense
$0
Net Income from Continuing Ops
-$8M
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$8M
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$8M
D&A
$12.0K
EBIT
-$8M
EBITDA
-$8M
EPS
-$1
EPS Diluted
-$1
marketcaparena.com
Cash Flow Statement
Item
Amount
Net Income
-$8M
Depreciation & Amortization
$12.0K
Stock-Based Compensation
$5M
Deferred Income Tax
$0
Other Non-Cash Items
-$492.5K
Change in Working Capital
$156.9K
OPERATING CASH FLOW
-$3M
Capital Expenditure
-$246.3K
Acquisitions (Net)
$445.4K
Purchases of Investments
$0
Sales/Maturities of Investments
$0
Other Investing Activities
-$11M
NET CASH FROM INVESTING
-$11M
Net Debt Issuance
$0
Common Stock Repurchased
$0
Common Dividends Paid
$0
Other Financing Activities
-$42.4K
NET CASH FROM FINANCING
$32M
FREE CASH FLOW
-$4M
Net Change in Cash
$43M
marketcaparena.com
← FY 2016
AAPG Overview
Q2 2017 →